RESUMEN

Objetivo: Evaluar la mejora en la adherencia terapéutica (AT) de una intervención basada en el seguimiento telefónico por parte del farmacéutico de atención primaria (FAP).Diseño: Ensayo clínico abierto aleatorizado con grupo control. Emplazamiento: Este estudio se realizó en el ámbito de la atención primaria por un equipo multidisciplinar de 13 centros de salud pertenecientes a 4 direcciones asistenciales de la Comunidad de Madrid durante el año 2021. Participantes: Pacientes polimedicados (60-74 años) que aceptasen participar y fueran clasificados como no adherentes según el test Morisky-Green. Se captaron 224 pacientes, de los cuales 87 fueron no adherentes. De estos se perdieron 15, aleatorizándose finalmente 72. Terminaron el estudio 71 pacientes, 33 en el grupo intervención y 38 en el grupo control. Intervenciones: Al grupo intervención se le incluyó en un programa de seguimiento telefónico que consistía en una entrevista para mejorar la adherencia en los meses 1, 2 y 3. Para evaluar la mejora se repetía el test Morisky-Green al 4.° mes. En el control únicamente se realizó el test de AT al 4.° mes. Mediciones principales: Adherencia, medida por el Morisky-Green al inicio y a los 4 meses. Resultados: En el grupo intervención el 72,7% de los pacientes pasaron a ser adherentes, mientras que en el grupo control el 34,2%, siendo la diferencia del 38,5% (IC 95%: 17,1-59,9) estadísticamente significativa (p=0,001). Conclusiones: Tras la intervención de seguimiento telefónico educacional-conductual a pacientes no adherentes por parte del FAP se mejora la AT de forma estadísticamente significativa en el grupo intervención respecto al grupo control.(AU)

Objective: Evaluate the improvement in therapeutic adherence of an intervention based on telephone monitoring by the primary care pharmacist. Design: Randomized open controlled trial. Location: This study was carried out in 2021 by a multidisciplinary team working with health professionals of thirteen health centers belonging to four health districts in Community of Madrid, Spain. ParticipantsThese were patients (60-74 years) with polipharmacy classified as non-adherent according to the Morisky-Green test. Two hundred and twenty-four patients were originally enrolled, 87 of them were non-adherents. Of these, 15 were lost and 72 were finally randomized. Seventy-one patients completed the study (33 intervention group and 38 control group). Interventions: Patients randomized to the intervention arm were included in a follow-up telephone program consisting of an interview at months 1, 2, and 3 to improve adherence. The Morisky-Green test was repeated at month 4 to assess improvement. In the control group this test was only performed at month 4. Main measurements: Adherence measured by Morisky-Green at baseline and at 4th month. Results: The 72.7% of patients in the intervention group became adherent while only 34.2% did in the control arm, being the difference 38.5% (95% CI: 17.1-59.9), statistically significant (P=.001). Conclusions: After a follow-up educational-behavioral telephone intervention in non-adherent patients by the primary care pharmacist, therapeutic adherence was improved statistically significantly in the intervention group compared with the control group.(AU)

Asunto(s)

RESUMEN

OBJECTIVE: Evaluate the improvement in therapeutic adherence of an intervention based on telephone monitoring by the primary care pharmacist. DESIGN: Randomized open controlled trial. LOCATION: This study was carried out in 2021 by a multidisciplinary team working with health professionals of thirteen health centers belonging to four health districts in Community of Madrid, Spain. PARTICIPANTS: These were patients (60-74 years) with polipharmacy classified as non-adherent according to the Morisky-Green test. Two hundred and twenty-four patients were originally enrolled, 87 of them were non-adherents. Of these, 15 were lost and 72 were finally randomized. Seventy-one patients completed the study (33 intervention group and 38 control group). INTERVENTIONS: Patients randomized to the intervention arm were included in a follow-up telephone program consisting of an interview at months 1, 2, and 3 to improve adherence. The Morisky-Green test was repeated at month 4 to assess improvement. In the control group this test was only performed at month 4. MAIN MEASUREMENTS: Adherence measured by Morisky-Green at baseline and at 4th month. RESULTS: The 72.7% of patients in the intervention group became adherent while only 34.2% did in the control arm, being the difference 38.5% (95% CI: 17.1-59.9), statistically significant (P=.001). CONCLUSIONS: After a follow-up educational-behavioral telephone intervention in non-adherent patients by the primary care pharmacist, therapeutic adherence was improved statistically significantly in the intervention group compared with the control group.

Asunto(s)

RESUMEN

The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64-81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (p < 0.001). There was no evidence of a beneficial effect of long-term courses of macrolides in preventing SARS-CoV-2 infection or the progression to worse outcomes in old patients with underlying chronic respiratory diseases and a high burden of comorbidity.